2 assets in Colorectal Squamous Cell Carcinoma

Therapeutic assets addressing Colorectal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Colorectal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Colorectal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)